Angelo Asa Clemenzi-Allen, MD
Infectious Disease · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
Offices
1 location
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Clemenzi-Allen’s office at (413) 537-6483 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A129001 · Current
Licensed to practise in California · since 2014 · expires 2027-12-31 · University of Massachusetts Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Infectious Disease
- American Board of Internal Medicine - Internal Medicine
Medicaid work
$67,032 in 2024
Medicaid paid $67,032 for 589 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 204 | $66,739 |
| Short return visit (20+ min) | 221 | $293 |
| Service | 164 | $0 |
| 2024 | 589 | 3 | 19 | $67,032 |
| 2023 | 455 | 4 | 22 | $52,276 |
| 2022 | 166 | 3 | 19 | $13,236 |
| 2021 | 524 | 6 | 76 | $52,390 |
| 2020 | 117 | 3 | 18 | $15,925 |
| 2019 | 12 | 1 | 12 | $3,691 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 205 | $50,544 |
| Return visit (30+ min) | 82 | $1,688 |
| Short return visit (20+ min) | 111 | $45 |
| Service | 57 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 120 | $13,236 |
| Short return visit (20+ min) | 28 | $0 |
| Service | 18 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 143 | $39,782 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; single dose | 209 | $11,168 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 24 | $960 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose | 12 | $480 |
| Short return visit (20+ min) | 28 | $0 |
| Service | 108 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 52 | $15,925 |
| Return visit (30+ min) | 13 | $0 |
| Service | 52 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 12 | $3,691 |
Drugs they prescribed that Part D paid
$119,446
Pharmacies billed $119,446 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 104) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
67 generic and 37 brand-name prescriptions · $119,446 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Biktarvy | 24 | $91,035 | $3,793 |
| Olanzapine | 22 | $172 | $8 |
Year by year
| 2024 | 104 | None | 0% (0) | 36% | $119,446 |
| 2023 | 100 | None | 0% (0) | 37% | $115,640 |
| 2022 | 36 | None | 0% (0) | 50% | $76,592 |
| 2021 | 50 | None | 0% (0) | 24% | $34,011 |
| 2020 | 42 | 15 | 0% (0) | 33% | $34,844 |
| 2019 | 355 | 16 | None | 31% | $246,968 |
| 2018 | 324 | 15 | None | 37% | $234,625 |
| 2017 | 154 | None | None | 45% | $116,955 |
| 2016 | 27 | None | None | 44% | $15,204 |
| 2015 | 135 | 17 | None | 23% | $10,186 |
| 2014 | 36 | None | None | None | $522 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Biktarvy | 12 | $48,063 | $4,005 |
| Divalproex Sodium Er | 12 | $630 | $52 |
| Testosterone Cypionate | 17 | $569 | $33 |
| Mirtazapine | 11 | $275 | $25 |
2022: 1 drug
| Symtuza | 11 | $48,615 | $4,420 |
2021: 2 drugs
| Finasteride | 12 | $148 | $12 |
| Amlodipine Besylate | 12 | $77 | $6 |
2019: 16 drugs
| Symtuza | 12 | $45,285 | $3,774 |
| Tivicay | 20 | $38,297 | $1,915 |
| Descovy | 22 | $37,996 | $1,727 |
| Omega-3 Acid Ethyl Esters | 13 | $1,109 | $85 |
| Niacin Er | 13 | $638 | $49 |
| Dapsone | 11 | $634 | $58 |
| Valacyclovir | 13 | $444 | $34 |
| Fluconazole | 11 | $232 | $21 |
| Ezetimibe | 12 | $163 | $14 |
| Atorvastatin | 15 | $162 | $11 |
| Omeprazole | 23 | $157 | $7 |
| Acyclovir | 12 | $136 | $11 |
| Amlodipine Besylate | 19 | $116 | $6 |
| Carvedilol | 21 | $92 | $4 |
| Azithromycin | 15 | $91 | $6 |
| Allopurinol | 12 | $79 | $7 |
2018: 9 drugs
| Descovy | 36 | $62,812 | $1,745 |
| Creon | 12 | $51,119 | $4,260 |
| Tivicay | 28 | $48,576 | $1,735 |
| Valacyclovir | 14 | $616 | $44 |
| Fluticasone Propionate | 16 | $165 | $10 |
| Azithromycin | 16 | $158 | $10 |
| Atorvastatin | 14 | $124 | $9 |
| Omeprazole | 12 | $77 | $6 |
| Amlodipine Besylate | 11 | $38 | $3 |
2017: 6 drugs
| Creon | 13 | $45,662 | $3,512 |
| Tivicay | 17 | $26,695 | $1,570 |
| Descovy | 14 | $22,199 | $1,586 |
| Gabapentin | 13 | $309 | $24 |
| Propranolol | 13 | $185 | $14 |
| Omeprazole | 13 | $59 | $5 |
2015: 2 drugs
| Effient | 12 | $3,881 | $323 |
| Metoprolol | 12 | $64 | $5 |
Money from drug and device companies
$32 in 2019
A payment is not proof that care is biased.
| Gilead Sciences | None | $32 | 1 payment
|
See the published payment
| Gilead Sciences | Meals · 2019-02-28 | None | $32 |
Professional record
- NPI
- 1770842684
- Licence
- CA A129001California A129001: Current · expires 2027-12-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X); Internal medicine (207R00000X)
- Mailing address
- 1785 Alabama St, San Francisco, CA, 94110
- NPI first listed
- 2012-05-11
- NPI last updated
- 2017-06-20
This is when the NPI record was last certified, not a medical board exam.